重组人生长激素治疗特发性矮小症的临床疗效及安全性研究  

Clinical efficacy and safety of recombinant human growth hormone in the treatment of idiopathic short stature

作　　者：蔡新喜 蔡清霞 谢巧金 CAI Xin-xi;CAI Qing-xia;XIE Qiao-jin(Department of Pediatrics,Longyan People's Hospital,Longyan City,Fujian Province,364000,China;Department of Pediatrics,Longyan Hospital of Traditional Chinese Medicine,Longyan City,Fujian Province,364000,China;Department of Pharmacy,the First Hospital of Longyan City,Longyan City,Fujian Province,364000,China)

机构地区：[1]福建省龙岩市人民医院儿科,福建龙岩364000 [2]福建省龙岩市中医院儿科,福建龙岩364000 [3]福建省龙岩市第一医院药剂科,福建龙岩364000

出　　处：《蛇志》2022年第1期41-43,59,共4页Journal of Snake

摘　　要：目的探讨重组人生长激素治疗特发性矮小症的临床效果及安全性。方法选取2018年2月~2021年2月收治的86例特发性矮小症患儿为研究对象,随机分为对照组和观察组,每组43例。对照组给予常规治疗,观察组使用重组人生长激素治疗,比较两组的治疗效果。结果治疗后,观察组的GV、PAH、Ht-SDSBA、Ht-SDSCA指标以及IGF-1、IGFBP-3水平均明显优于对照组,差异均有统计学意义(均P<0.05);而两组患儿治疗后的BA指标比较,差异无统计学意义(P>0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人生长激素治疗小儿特发性矮小症能有效提高患儿生长速度,促进生长发育,且安全性高。Objective To investigate the efficacy and safety of recombinant human growth hormone in the treatment of idiopathic short stature.Methods 86 patients with idiopathic short stature from February 2018 to February 2021 were randomly divided into control group and observation group,43 cases in each group.The control group was given conventional treatment,and the observation group was treated with recombinant human growth hormone.Results After treatment,GV,PAH,HT sdsba and HT sdsca in the observation group were better than those in the control group;the levels of IGF-1 and IGFBP-3 in the observation group were also better than those in the control group(P<0.05 for each);there was no significant difference in Ba between the two groups after treatment(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For the clinical treatment of children with idiopathic short stature,the application of recombinant human growth hormone can promote the growth of children,accelerate the growth rate,and will not significantly increase the incidence of adverse reactions,the safety is relatively reliable.

关 键 词：重组人生长激素 特发性矮小症 疗效 安全性 

分 类 号：R977[医药卫生—药品]